Frederick Ling is a Cardiology physician affiliated with University of Rochester Medical Center. OpenAlex indexes 107 publications with 1,922 citations (h-index 22).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
601 Elmwood Ave
Rochester, NY 146420001
Telephone
585-275-4751Registry record last updated 3 Jul 2023.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- MAGENTA MEDICAL INCProgram year20252 payments
- Edwards Lifesciences CorporationProgram year20259 payments
- Abbott LaboratoriesProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
79.6%Beta blocker18.6%Metoprolol Succinate52%Carvedilol34%Metoprolol Tartrate14%Part D<11 patientsStatin16.7%Atorvastatin Calcium83%Rosuvastatin Calcium17%Part D<11 patients+ 10 more classes in this area
Blood & clotting
17.1%P2Y12 inhibitor9.9%Clopidogrel100%Part D≥16 patientsFactor Xa inhibitor7.2%Eliquis100%Part D≥11 patientsMetabolism & gastrointestinal
3.3%SGLT2 inhibitor3.3%Jardiance100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Ad Hoc Percutaneous Coronary Intervention in Stable Patients With Multivessel or Unprotected Left Main Disease
JACC: Cardiovascular Interventions
2023 - Short-term Deaths After Percutaneous Coronary Intervention Discharge: Prevalence, Risk Factors, and Hospital Risk-Adjusted Mortality
Journal of the Society for Cardiovascular Angiography & Interventions
2023 - New York Risk Model and Simplified Risk Score for In-Hospital/30-Day Mortality for Percutaneous Coronary Intervention
The American Journal of Cardiology
2023 - Percutaneous Coronary Intervention With and Without Intravascular Ultrasound for Patients With Complex Lesions: Utilization, Mortality, and Target Vessel Revascularization
Circulation Cardiovascular Interventions
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Ann Falsey, MD
University of Rochester Medical Center
Supriya Mohile, MD
University of Rochester Medical Center
Paul Barr, MD
University of Rochester Medical Center
Christopher Ritchlin, MD
University of Rochester Medical Center
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Scott Solomon, MD
Brigham and Women's Hospital
Eric Topol, MD
Scripps Research Institute (Scripps Research)
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”